Natco Settles Over Canadian Revlimid Rival
Deal Comes After Indian Firm Reports Falling Sales Last Year
India’s Natco has struck a deal with Celgene to settle litigation over its proposed generic lenalidomide rival to Revlimid in Canada. News of the settlement came shortly after the Indian firm reported a decline in quarterly and annual revenues following supply chain disruptions caused by the coronavirus crisis.
